Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Capital Expenditures (2023 - 2024)

Onconetix (ONCO) has disclosed Capital Expenditures for 2 consecutive years, with $3874.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures rose 100.06% to $3874.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $28471.0, a 762.76% increase, with the full-year FY2024 number at $28471.0, up 762.76% from a year prior.
  • Capital Expenditures was $3874.0 for Q4 2024 at Onconetix, up from $2313.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.1 million in Q2 2023 to a low of -$6.1 million in Q4 2023.